At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 7 enrolled
Drug / intervention
Lirilumab +1 moredrug
Likely dose
Lirilumab 3 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Lirilumab (Anti-KIR mAb) Combined With Rituximab for Relapsed, Refractory or High-risk Untreated Patients With Chronic Lymphocytic Leukemia (CLL)
In Brief
A Phase 2 clinical trial evaluating Lirilumab and Rituximab for Leukemia and 2 related conditions. Completed, enrolled 7 participants across 1 site.
Detailed Summary
The goal of this clinical research study is to learn if lirilumab in combination with rituximab can help to control either CLL or Small lymphocytic lymphoma (SLL). The safety of the drug combination will also be studied.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLeukemia, Chronic Lymphocytic Leukemia, Lymphocytic Leukemia
CountriesUnited States
CollaboratorsBristol-Myers Squibb
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartJun 2015
First PostedJun 2015
Primary CompletionAug 2019
TodayJul 2026
First PostedJun 25, 2015
Enrollment StartJun 23, 2015
Primary CompletionAug 15, 2019
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 11.0 years ago
Interventions
Lirilumabdrug
3 mg/kg by vein given on Day 1 of each 28 day cycle.
Rituximabdrug
375 mg/m2 by vein weekly for the first 4 weeks on Days 1,8, 15, and 22 of Cycle 1. After Cycle 1, given on Day 1 of Cycles 2 - 12.